東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Pharmacokinetics of the dietary supp...

Persky, Adam Mitchell.

FindBook

Google Book

Amazon

博客來

Pharmacokinetics of the dietary supplement creatine.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Pharmacokinetics of the dietary supplement creatine./
作者:	Persky, Adam Mitchell.
面頁冊數:	100 p.
附註:	Chairs: Gayle A. Brazeau; Gunther Hochhaus.
Contained By:	Dissertation Abstracts International63-06B.
標題:	Health Sciences, Nutrition. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3056773
ISBN:	9780493719962

Pharmacokinetics of the dietary supplement creatine.
Persky, Adam Mitchell.

Pharmacokinetics of the dietary supplement creatine. - 100 p.

Chairs: Gayle A. Brazeau; Gunther Hochhaus.

Thesis (Ph.D.)--University of Florida, 2002.

Creatine (Cr) is a naturally occurring compound obtained by humans from both endogenous production and through the diet. Increases in Cr stores through supplementation have shown physiological benefits in athletes, animal-based disease models, and clinically in various patient populations. Although the 'pharmacological' outcome measures of Cr have been investigated, the behavior of Cr in blood and muscle are still not fully understood. If Cr is ever to be used clinically as a treatment for disease, then a pharmacokinetic profile is needed to establish an optimal dosing regimen. The purpose of this study was to investigate the pharmacokinetics of Cr after oral administration in plasma and microdialysis based muscle levels. First a sensitive and specific HPLC assay was developed and used to analyze creatine in microdialysis samples, human plasma, to determine product purity and to determine plasma protein binding. Six healthy males completed an open-label study consisting of full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 d of a Cr administration (71 mg kg-1 q6h). Body weight during the course of Cr administration increased a significant 0.8 kg. A single oral dose was found to have a clearance (CUF) = 0.20 +/- 0.066 L h-1 kg-1, CMAX = 102.1 +/- 11.2 mg L -1. At steady-state, CL/F decreased to 0.12 +/- 0.016 L h-1, CMAX increased to 162.2 +/- 30.01 mg L-1 and accumulation was estimated at 1.59. Penetration of Cr into the interstitial muscle space, as defined as AUCmuscle/AUC plasma, was 0.47 +/- 0.09 and 0.37 +/- 0.27 for single dose and steady-state, respectively. Various models were used to simultaneously fit the plasma and interstitial muscle data. Fitting was best accomplished with a saturable absorption and first order elimination. In conclusion, repeated dosing of Cr caused a reduction in clearance and volume of distribution most likely as a function of saturation of the skeletal muscle pool of Cr.

ISBN: 9780493719962Subjects--Topical Terms:

1017801
Health Sciences, Nutrition.

Pharmacokinetics of the dietary supplement creatine.
LDR:02923nam 2200289 a 45 001 969123
005 20110920
008 110921s2002 eng d
020 $a 9780493719962
035 $a (UMI)AAI3056773
035 $a AAI3056773
040 $a UMI $c UMI
100 1 $a Persky, Adam Mitchell. $3 1293178
245 1 0 $a Pharmacokinetics of the dietary supplement creatine.
300 $a 100 p.
500 $a Chairs: Gayle A. Brazeau; Gunther Hochhaus.
500 $a Source: Dissertation Abstracts International, Volume: 63-06, Section: B, page: 2801.
502 $a Thesis (Ph.D.)--University of Florida, 2002.
520 $a Creatine (Cr) is a naturally occurring compound obtained by humans from both endogenous production and through the diet. Increases in Cr stores through supplementation have shown physiological benefits in athletes, animal-based disease models, and clinically in various patient populations. Although the 'pharmacological' outcome measures of Cr have been investigated, the behavior of Cr in blood and muscle are still not fully understood. If Cr is ever to be used clinically as a treatment for disease, then a pharmacokinetic profile is needed to establish an optimal dosing regimen. The purpose of this study was to investigate the pharmacokinetics of Cr after oral administration in plasma and microdialysis based muscle levels. First a sensitive and specific HPLC assay was developed and used to analyze creatine in microdialysis samples, human plasma, to determine product purity and to determine plasma protein binding. Six healthy males completed an open-label study consisting of full pharmacokinetic analysis following a single oral dose of Cr monohydrate (71 mg kg-1) and at steady-state after 6 d of a Cr administration (71 mg kg-1 q6h). Body weight during the course of Cr administration increased a significant 0.8 kg. A single oral dose was found to have a clearance (CUF) = 0.20 +/- 0.066 L h-1 kg-1, CMAX = 102.1 +/- 11.2 mg L -1. At steady-state, CL/F decreased to 0.12 +/- 0.016 L h-1, CMAX increased to 162.2 +/- 30.01 mg L-1 and accumulation was estimated at 1.59. Penetration of Cr into the interstitial muscle space, as defined as AUCmuscle/AUC plasma, was 0.47 +/- 0.09 and 0.37 +/- 0.27 for single dose and steady-state, respectively. Various models were used to simultaneously fit the plasma and interstitial muscle data. Fitting was best accomplished with a saturable absorption and first order elimination. In conclusion, repeated dosing of Cr caused a reduction in clearance and volume of distribution most likely as a function of saturation of the skeletal muscle pool of Cr.
590 $a School code: 0070.
650 4 $a Health Sciences, Nutrition. $3 1017801
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0570
690 $a 0572
710 2 0 $a University of Florida. $3 718949
773 0 $t Dissertation Abstracts International $g 63-06B.
790 $a 0070
790 1 0 $a Brazeau, Gayle A., $e advisor
790 1 0 $a Hochhaus, Gunther, $e advisor
791 $a Ph.D.
792 $a 2002
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3056773